Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on progression-free survival (PFS), and rates and duration of minimal residual disease negativity (MRD–) in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) and comorbidities.

Kirsten Fischer,Othman Al-Sawaf,Jasmin Bahlo,Anna-Maria Fink,Maneesh Tandon,Mark Dixon,Sandra Robrecht,Kathryn Humphrey,Sebastian Böttcher,Eugen Tausch,Rod A. Humerickhouse,Barbara Eichhorst,Clemens-Martin Wendtner,Anton W. Langerak,Karl Anton Kreuzer,Valentin Goede,Stephan Stilgenbauer,Mehrdad Mobasher,Matthias Ritgen,Michael Hallek,Cll Study Investigators

Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on progression-free survival (PFS), and rates and duration of minimal residual disease negativity (MRD–) in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) and comorbidities.

2019

7502Background: The multinational, open-label, phase 3 CLL14 trial compared fixed-duration targeted VenG treatment with chlorambucil-obinutuzumab (ClbG) in previously untreated pts with CLL and com...

Keywords:

Pathology
Chronic lymphocytic leukemia
Oncology
Obinutuzumab
Venetoclax
Progression-free survival
Minimal Residual Disease Negativity
Medicine
Internal medicine
fixed duration

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations